CBI’s Premiere Forum on Bio/Pharmaceutical and Medical Device Corporate Integrity Agreements (CIAs)

Washington, DC

When manufacturers settle with the government for alleged wrongdoing — many times focused on fraudulent promotion or kickback allegations — in addition to hefty fines, the organization enters into a Corporate Integrity Agreement (CIA) with the OIG. While each agreement differs by focusing specifically on each manufacturer's conduct issues, these agreements are an invaluable asset to compliance teams as they give insight into the government's expectations and standards for various compliance challenges.

In this forum, hear best practices that have been developed following an integrity obligation. Attendees come from both companies currently operating under a CIA and those that are not. Session leaders explain how they improved or changed their processes and how these enhancements can be applied at any company to develop an overall more efficient and effective compliance program.

  • Understand the collaboration between state and federal authorities regarding integrity obligations

  • Highlight key takeaways from the most recent CIA settlements

  • Implement effective and efficient training programs

  • Develop policies and procedures for capturing and disclosing HCP spend

  • Discuss methodology for establishing a process to develop FMV

  • Implement best practices in field-based auditing and monitoring

For more information or to register, please contact the Center for Business Intelligence toll free by phone at 1-800-817-8601 or via e-mail at [email protected].